Your Article Summary
FDA Advisory Committee recommendation on SEROQUEL XR Supplemental New Drug Applications
AstraZeneca, 04/09/09
The U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee conducted a review of the safety and efficacy of supplemental new drug applications for SEROQUEL XR extended-release tablets proposed for the treatment of major depressive disorder and generalized anxiety disorder.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/10/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Article Search
Sponsor


See Latest Articles


